PHAXIAM Therapeutics S.A. Asset Resilience Ratio

Latest as of June 2024: 3.74%

PHAXIAM Therapeutics S.A. asset resilience ratio. PHAXIAM Therapeutics S.A. (PHXM) has an Asset Resilience Ratio of 3.74% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHAXIAM Therapeutics S.A. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€1.46 Million

≈ $1.71 Million USD Cash + Short-term Investments

Total Assets

€39.11 Million

≈ $45.72 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of PHAXIAM Therapeutics S.A. (2016–2023)

Asset resilience ratio of PHAXIAM Therapeutics S.A. from 2016 to 2023. This chart shows how PHAXIAM Therapeutics S.A.'s Asset Resilience Ratio has changed over time. Read debt load of PHAXIAM Therapeutics S.A. for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down PHAXIAM Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PHXM total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€1.46 Million	3.74%
Short-term Investments	€0.00	0%
Total Liquid Assets	€1.46 Million	3.74%

Asset Resilience Insights

Limited Liquidity: PHAXIAM Therapeutics S.A. maintains only 3.74% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PHAXIAM Therapeutics S.A. Industry Peers by Asset Resilience Ratio

Compare PHAXIAM Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

PHAXIAM Therapeutics S.A. Asset Resilience Ratio by Year (2016–2023)

PHAXIAM Therapeutics S.A. asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for PHAXIAM Therapeutics S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	20.41%	€10.47 Million ≈ $12.25 Million	€51.31 Million ≈ $59.98 Million	-64.35pp
2022-12-31	84.77%	€38.83 Million ≈ $45.40 Million	€45.81 Million ≈ $53.56 Million	+33.58pp
2021-12-31	51.19%	€34.18 Million ≈ $39.96 Million	€66.77 Million ≈ $78.06 Million	-4.10pp
2020-12-31	55.29%	€44.45 Million ≈ $51.97 Million	€80.40 Million ≈ $94.00 Million	-6.45pp
2019-12-31	61.74%	€73.19 Million ≈ $85.56 Million	€118.55 Million ≈ $138.59 Million	-18.32pp
2018-12-31	80.06%	€134.37 Million ≈ $157.09 Million	€167.84 Million ≈ $196.22 Million	-3.66pp
2016-12-31	83.72%	€37.65 Million ≈ $44.01 Million	€44.97 Million ≈ $52.57 Million	--

pp = percentage points

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30677 Global

#573 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.10

All Time High

€283.83